These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19184975)

  • 21. A Bayesian semiparametric latent variable approach to causal mediation.
    Kim C; Daniels M; Li Y; Milbury K; Cohen L
    Stat Med; 2018 Mar; 37(7):1149-1161. PubMed ID: 29250817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Causal inference in longitudinal comparative effectiveness studies with repeated measures of a continuous intermediate variable.
    Wang CP; Jo B; Brown CH
    Stat Med; 2014 Sep; 33(20):3509-27. PubMed ID: 24577715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mediation analysis for count and zero-inflated count data without sequential ignorability and its application in dental studies.
    Guo Z; Small DS; Gansky SA; Cheng J
    J R Stat Soc Ser C Appl Stat; 2018 Feb; 67(2):371-394. PubMed ID: 30983638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.
    Shen W; Ning J; Yuan Y
    Stat Med; 2015 Jun; 34(13):2104-15. PubMed ID: 25756852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Instruments and bounds for causal effects under the monotonic selection assumption.
    Taguri M; Chiba Y
    Int J Biostat; 2012 Aug; 8(1):24. PubMed ID: 22944723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multilevel autoregressive mediation models: Specification, estimation, and applications.
    Zhang Q; Wang L; Bergeman CS
    Psychol Methods; 2018 Jun; 23(2):278-297. PubMed ID: 29172610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marginal structural models for estimating principal stratum direct effects under the monotonicity assumption.
    Chiba Y
    Biom J; 2011 Nov; 53(6):1025-34. PubMed ID: 22020774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity analyses for the principal ignorability assumption using multiple imputation.
    Wang C; Zhang Y; Mealli F; Bornkamp B
    Pharm Stat; 2023 Jan; 22(1):64-78. PubMed ID: 36053974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian Approach for Estimating the Survivor Average Causal Effect When Outcomes Are Truncated by Death in Cluster-Randomized Trials.
    Tong G; Li F; Chen X; Hirani SP; Newman SP; Wang W; Harhay MO
    Am J Epidemiol; 2023 Jun; 192(6):1006-1015. PubMed ID: 36799630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.
    Scharfstein DO; Daniels MJ; Robins JM
    Biostatistics; 2003 Oct; 4(4):495-512. PubMed ID: 14557107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity analysis for principal ignorability violation in estimating complier and noncomplier average causal effects.
    Nguyen TQ; Stuart EA; Scharfstein DO; Ogburn EL
    Stat Med; 2024 Aug; 43(19):3664-3688. PubMed ID: 38890728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of causal estimation of effects in mediation analyses.
    Ten Have TR; Joffe MM
    Stat Methods Med Res; 2012 Feb; 21(1):77-107. PubMed ID: 21163849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    J Biopharm Stat; 2020; 30(1):69-88. PubMed ID: 31017843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian inference for the causal effect of mediation.
    Daniels MJ; Roy JA; Kim C; Hogan JW; Perri MG
    Biometrics; 2012 Dec; 68(4):1028-36. PubMed ID: 23005030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the sensitivity of methods for estimating principal causal effects.
    Stuart EA; Jo B
    Stat Methods Med Res; 2015 Dec; 24(6):657-74. PubMed ID: 21971481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causal Mediation Analyses for Randomized Trials.
    Lynch KG; Cary M; Gallop R; Ten Have TR
    Health Serv Outcomes Res Methodol; 2008; 8(2):57-76. PubMed ID: 19484136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using structural-nested models to estimate the effect of cluster-level adherence on individual-level outcomes with a three-armed cluster-randomized trial.
    Brumback BA; He Z; Prasad M; Freeman MC; Rheingans R
    Stat Med; 2014 Apr; 33(9):1490-502. PubMed ID: 24288357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weighting in instrumental variables and G-estimation.
    Joffe MM; Brensinger C
    Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.